南京市鼓楼区中山路321号
dr.wu@nju.edu.cn
13809022921工作经历
2005/6-，南京大学医学院附属鼓楼医院，主任医师
1999/9-2005/5，南京大学医学院附属鼓楼医院，副主任医师
1989/12-1999/8，南京大学医学院附属鼓楼医院，主治医师
1984/8-1989/12，江苏淮安市传染病防治院，住院医师
荣誉奖励
2024-10，新型冠状病毒感染的临床特征与防治策略. 江苏省科学技术奖三等奖（第一完成人）
2023-11，新型冠状病毒感染（COVID-19）的临床特征与防治策略研究. 江苏省瑞华慈善基金临床研究创新奖三等奖（第一完成人）
2024-10，新型冠状病毒感染的临床诊治与疫苗保护机制研究. 南京预防医学科技奖一等奖（第九完成人）
2019，慢性乙型肝炎的免疫发病机制及临床相关研究. 江苏省医学科技奖二等奖（第一完成人）
2016, 慢性乙型肝炎患者免疫调节机制研究及其在治疗中的应用. 南京市科技进步一等奖（第一完成人）
2013, 外周血B细胞活化及抗HBV的临床应用，江苏省医学新技术引进奖一等奖（第一完成人）
2012, 流式检测外周血T细胞表面PD-1的表达对临床慢乙肝患者免疫状态的判断及抗病毒疗效的评估，江苏省医学新技术引进奖二等奖（第一完成人）
学术任职
2019-，中华医学会肝病学分会 委员
2019-2024，中华医学会感染病学分会 委员
2020-2023，江苏省感染病学会主任委员
代表性成果
（1）Wang J, Zhang Z, Zhu L, Fan T, Xiong Y, Zhang S, Jiang C, Yin S, Tong X, Xia J, Yan X, Yao R, Shi Y, Liu X, Zhu C*, Wu C*, Huang R*. Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase. Clin Gastroenterol Hepatol. 2026;17:S1542-3565(26)00134-5.
（2）Wang J, Ding W, Liu J, Liu Y, Yan X, Xia J, Wu W, Jia B, Chen Y, Gao D, Hong S, Wang X, Wang L, Tong X, Yin S, Zhang Z, Li J, Huang R*, Wu C*. Association of Coexistent Hepatitis B Surface Antigen and Antibody With Severe Liver Fibrosis and Cirrhosis in Treatment-Naive Patients With Chronic Hepatitis B. JAMA Netw Open. 2022;5(6):e2216485.
（3）Wang J, Fan T, Zhang Z, Zhu L, Zhang S, Xiong Y, Shan C, Jiang C, Yin S, Tong X, Yao R, Xia J, Yan X, Shi Y, Chen Y, Liu X, Wang H, Zhang H, Zhu C, Zhang Q, Wu C*, Huang R*. Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment. Emerg Microbes Infect. 2025;14(1):2552718.
（4）Cao F, Wang J, Xiong Y, Zhang Y, Zhang X, Fan T, Zhu L, Zhang S, Zhang Z, Pan Y, Li Y, Jiang C, Xia J, Shi Y, Yan X, Chen Y, Liu X, Zhu C*, Wu C*, Huang R*. Antiviral treatment response to nucleos(t)ide analogues in chronic hepatitis B patients with normal alanine aminotransferase levels: a retrospective multi-center study. Emerg Microbes Infect. 2025;14(1):2589550.
（5）Wang J, Zhang Z, Yin S, Zhang S, Zhu L, Pan Y, Fan T, Cao F, Xiong Y, Jiang C, Wang G, Yang Y, Jia B, Liu J, Xia J, Yan X, Li J, Zhu C, Liu X, Chen Y, Wu C*, Huang R*. Favourable Prognosis of Patients With Untreated HBeAg-Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL. Aliment Pharmacol Ther. 2025;61(3):472-80.
（6）Huang R, Do AT, Toyoda H, Li J, Yasuda S, Tsai PC, Yeh ML, Trinh H, Chau A, Huang DQ, Ogawa E, Ito T, Kozuka R, Atsukawa M, Marciano S, Honda T, Watanabe T, Itokawa N, Preda CM, Tseng CH, Barreira, Inoue K, Takahashi H, Uojima H, Kawashima K, Hsu YC, Marin RI, Sandra I, Ishigami M, Li J, Zhang J, Do S, Maeda M, Lee DH, Chuang WL, Dai CY, Huang JF, Huang CF, Cheung R, Buti M, Tanaka Y., Yuen M. F., Enomoto M., Gadano A., Lim S. G., Yu M. L., Wu C*, Nguyen MH*. Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B Study. Aliment Pharmacol Ther. 2025;62(3):349-58.
（7）Xue R, Wang J, Zhan J, Zhang Z, Jiang S, Liu J, Wang L, Yan X, Yin S, Tong X, Ding W, Li J, Chen Y, Huang R*, Wu C*. Prevalence and clinical significance of HBeAg-positive chronic hepatitis B patients with and without anti-HBe antibody. Virulence. 2025;16(1):2534079.
（8）Wang J, Zhu L, Zhang S, Zhang Z, Fan T, Cao F, Xiong Y, Pan Y, Li Y, Jiang C, Yin S, Tong X, Xiong Y, Xia J, Yan X, Liu Y, Liu X, Chen Y, Li J, Zhu C*, Wu C*, Huang R*. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA. Emerg Microbes Infect. 2024;13(1):2339944.
（9）Wang J, Zhang Z, Zhu L, Zhang Q, Zhang S, Pan Y, Liu J, Cao F, Fan T, Xiong Y, Yin S, Yan X, Chen Y, Zhu C, Li J, Liu X, Wu C*, Huang R*. Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B. Virulence. 2024;15(1):2404965.
（10）Wang J, Yan X, Zhu L, Liu J, Qiu Y, Li Y, Liu Y, Xue R, Zhan J, Jiang S, Geng Y, Wan Y, Li M, Mao M, Gao D, Yin S, Tong X, Xia J, Ding W, Chen Y, Li J, Zhu C*, Huang R*, Wu C*. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther. 2023;57(5):464-474.
（11）Zhang S, Wang J, Zhang Q, Pan Y, Zhang Z, Geng Y, Jia B, Li Y, Xiong Y, Yan X, Li J, Wang H*, Wu C*, Huang R*. Association of liver function and prognosis in patients with severe fever with thrombocytopenia syndrome. PLoS Negl Trop Dis. 2024;18(4):e0012068.
（12）Chen Y, Shen H, Huang R, Tong X, Wu C*. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect Dis 2021;21(8):1071-1072.
（13）Chen Y, Tong X, Li Y, Gu B, Yan J, Liu Y, Shen H, Huang R*, Wu C*. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 2020;16(9):e1008796.
（14）Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, Zhang B, Xu T, Ji F, Zhao Y, Cheng J, Wang Y, Shao H, Hong S, Cao Q, Li C, Zhao XA, Zou L, Sang D, Zhao H, Guan X, Chen X, Shan C, Xia J, Chen Y, Yan X, Wei J, Zhu C*, Wu C*. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis. 2020;14(5):e0008280.
（15）Xia J, Huang R, Chen Y, Liu Y, Wang J, Yan X, Zhang Z, Wu C*. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharmacol Ther. 2020;51(11):1180-1187.